InvestSMART

BCAL Diagnostics Limited (ASX: BDX) - Announcements

- Current share price for BDX : $0.086

ASX company news and announcements for BCAL Diagnostics Limited (BDX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All BCAL Diagnostics Limited (BDX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than BCAL Diagnostics Limited (BDX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for BCAL Diagnostics Limited (BDX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$32 Letter to Shareholders re Annual General Meeting 18 Sep 2026 8:22AM $0.086 $0.086 fallen by 0%
$32 Notice of Annual General Meeting/Proxy Form 18 Sep 2026 8:22AM $0.086 $0.086 fallen by 0%
$32 Clarification of BCAL's Position in Relation to GSS 10 Sep 2026 1:19PM $0.065 $0.086 risen by 32.31%
$32 BCAL Seeks Board Change at Genetic Signatures 3 Sep 2026 12:40PM $0.069 $0.086 risen by 24.64%
$32 Investor Presentation September 2026 3 Sep 2026 11:47AM $0.069 $0.086 risen by 24.64%
$32 Meet The CEO FY 2026 Results Webinar 3 Sept 2026 at 1PM 31 Aug 2026 2:30PM $0.066 $0.086 risen by 30.30%
$32 Appendix 4G and Corporate Governance Statement 28 Aug 2026 3:46PM $0.065 $0.086 risen by 32.31%
$32 Appendix 4E and Annual Report to shareholders 28 Aug 2026 3:44PM $0.065 $0.086 risen by 32.31%
$32 BCAL Takes Interest in Genetic Signatures to 18.46% 26 Aug 2026 8:57AM $0.052 $0.086 risen by 65.38%
$32 Change in Substantial Shareholder Notice for GSS 26 Aug 2026 8:35AM $0.052 $0.086 risen by 65.38%
$32 Notification regarding unquoted securities - BDX 25 Aug 2026 6:53PM $0.052 $0.086 risen by 65.38%
$32 Notification regarding unquoted securities - BDX 21 Aug 2026 6:27PM $0.058 $0.086 risen by 48.28%
$32 Proposed issue of securities - BDX 21 Aug 2026 6:18PM $0.058 $0.086 risen by 48.28%
$32 BCAL Secures Funding for FY2027 Update 21 Aug 2026 6:14PM $0.058 $0.086 risen by 48.28%
$32 Bioshares Conference Investor Presentation 6 Aug 2026 9:34AM $0.065 $0.086 risen by 32.31%
$32 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jul 2026 8:38AM $0.073 $0.086 risen by 17.81%
$32 Notification regarding unquoted securities - BDX 14 Jul 2026 6:51PM $0.076 $0.086 risen by 13.16%
$32 Notification regarding unquoted securities - BDX 14 Jul 2026 6:44PM $0.076 $0.086 risen by 13.16%
$32 Notification regarding unquoted securities - BDX 14 Jul 2026 6:32PM $0.076 $0.086 risen by 13.16%
$32 Notification regarding unquoted securities - BDX 14 Jul 2026 6:20PM $0.076 $0.086 risen by 13.16%
$32 Becoming a substantial holder for GSS 2 Jul 2026 5:13PM $0.072 $0.086 risen by 19.44%
$32 BCAL to Acquire Shares in Genetic Signatures 2 Jul 2026 10:04AM $0.071 $0.086 risen by 21.13%
$32 BCAL Secures Funding for FY2027 29 Jun 2026 9:57AM $0.078 $0.086 risen by 10.26%
$32 BCAL Develops New Blood Test for Breast Cancer Recurrence 18 Jun 2026 9:52AM $0.060 $0.086 risen by 43.33%
$32 Validation Agreement Signed with Sonic USA, for Breastest V2 28 May 2026 8:25AM $0.080 $0.086 risen by 7.50%

1 - 25 of 273 results

Page 1 of 11

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.